Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7142509 | 0.82 | CYP1A2 (0.37) | MEN1KMT2ACYP1A2MAPTCYP2C19 | |
| SCHEMBL7102908 | 0.81 | MEN1 (0.36) | MEN1KMT2ACYP1A2MAPTCYP2C19 | |
| SCHEMBL7103695 | 0.81 | SIRT6 (0.33) | MEN1KMT2ACYP1A2MAPTKDM4E | |
| SCHEMBL7149878 | 0.77 | ALDH1A1 (0.37) | MEN1KMT2ACYP1A2MAPTCYP2C19 | |
| SCHEMBL7100904 | 0.77 | MAPT (0.33) | KMT2ACYP1A2MAPTCYP2C19CYP3A4 | |
| SCHEMBL7103698 | 0.77 | ALDH1A1 (0.39) | MEN1KMT2ACYP1A2MAPTCYP2C19 | |
| SCHEMBL7102160 | 0.75 | HTR1A (0.36) | MEN1KMT2ACYP1A2MAPTCYP2C19 | |
| SCHEMBL7098652 | 0.74 | CYP1A2 (0.33) | MEN1KMT2ACYP1A2MAPTCYP2C19 | |
| SCHEMBL7097632 | 0.73 | MAPT (0.36) | KMT2ACYP1A2MAPTCYP2C19CYP3A4 | |
| SCHEMBL8865283 | 0.72 | KDM4E (0.38) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073850-A1 | 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use | ABBOTT LABORATORIES | 2003-04-17 | — | — | US | disclosed |
| US-6503935-B1 | Treating urinary incontinence or retrograde ejaculation | ABBOTT LABORATORIES | 2003-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073850-A1 | 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use | ADRA1D, ADRB1, ADRA1A | MEN1 3832/4885KMT2A 1672/4885CYP1A2 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.